中国现代医药杂志
中國現代醫藥雜誌
중국현대의약잡지
MODERN MEDICINE JOURNAL OF CHINA
2014年
7期
38-41
,共4页
自体DC-CIK细胞%实体瘤%化疗%生存质量
自體DC-CIK細胞%實體瘤%化療%生存質量
자체DC-CIK세포%실체류%화료%생존질량
Autologous DC-CIK cells%Solid tumor%Chemotherapy%Quality of life
目的:观察化疗联合自体DC-CIK细胞回输治疗晚期恶性实体瘤的近期疗效。方法观察单纯化疗(对照组)和化疗联合自体DC-CIK细胞回输(联合组)治疗晚期恶性实体肿瘤疗效,主要观察指标:治疗前后外周血细胞因子、肿瘤标志物、胃肠道反应及骨髓抑制、生活质量、KPS评分。结果对照组20例治疗后CR 0例,PR 1例,MR 2例,SD 7例;PD 10例,缓解率为15%,DCR为50%。联合组治疗后CR 1例,PR 2例,MR 4例,SD 10例,PD 3例,缓解率35%,DCR为85%。两组DCR比较差异有统计学意义(χ2=5.58,P<0.05)。生存质量指标癌性疼痛、精神、睡眠、疲乏无力联合组比对照组改善明显,两组比较差异都有统计学意义(P<0.05);联合组和对照组胃肠道反应比较差异无统计学意义(χ2=1.71,P<0.05);联合组和对照组骨髓抑制情况比较差异有统计学意义(χ2=4.91,P<0.05);联合组治疗前后肿瘤标志物及外周血细胞因子计数变化比较无统计学差异(P>0.05)。结论自体DC-CIK细胞回输联合化疗治疗晚期恶性实体瘤DCR比单纯化疗者高,并且能够改善晚期肿瘤患者生存质量、KPS评分,减轻化疗后骨髓抑制情况,但胃肠道反应无明显差异。肿瘤标志物及细胞因子无明显变化。
目的:觀察化療聯閤自體DC-CIK細胞迴輸治療晚期噁性實體瘤的近期療效。方法觀察單純化療(對照組)和化療聯閤自體DC-CIK細胞迴輸(聯閤組)治療晚期噁性實體腫瘤療效,主要觀察指標:治療前後外週血細胞因子、腫瘤標誌物、胃腸道反應及骨髓抑製、生活質量、KPS評分。結果對照組20例治療後CR 0例,PR 1例,MR 2例,SD 7例;PD 10例,緩解率為15%,DCR為50%。聯閤組治療後CR 1例,PR 2例,MR 4例,SD 10例,PD 3例,緩解率35%,DCR為85%。兩組DCR比較差異有統計學意義(χ2=5.58,P<0.05)。生存質量指標癌性疼痛、精神、睡眠、疲乏無力聯閤組比對照組改善明顯,兩組比較差異都有統計學意義(P<0.05);聯閤組和對照組胃腸道反應比較差異無統計學意義(χ2=1.71,P<0.05);聯閤組和對照組骨髓抑製情況比較差異有統計學意義(χ2=4.91,P<0.05);聯閤組治療前後腫瘤標誌物及外週血細胞因子計數變化比較無統計學差異(P>0.05)。結論自體DC-CIK細胞迴輸聯閤化療治療晚期噁性實體瘤DCR比單純化療者高,併且能夠改善晚期腫瘤患者生存質量、KPS評分,減輕化療後骨髓抑製情況,但胃腸道反應無明顯差異。腫瘤標誌物及細胞因子無明顯變化。
목적:관찰화료연합자체DC-CIK세포회수치료만기악성실체류적근기료효。방법관찰단순화료(대조조)화화료연합자체DC-CIK세포회수(연합조)치료만기악성실체종류료효,주요관찰지표:치료전후외주혈세포인자、종류표지물、위장도반응급골수억제、생활질량、KPS평분。결과대조조20례치료후CR 0례,PR 1례,MR 2례,SD 7례;PD 10례,완해솔위15%,DCR위50%。연합조치료후CR 1례,PR 2례,MR 4례,SD 10례,PD 3례,완해솔35%,DCR위85%。량조DCR비교차이유통계학의의(χ2=5.58,P<0.05)。생존질량지표암성동통、정신、수면、피핍무력연합조비대조조개선명현,량조비교차이도유통계학의의(P<0.05);연합조화대조조위장도반응비교차이무통계학의의(χ2=1.71,P<0.05);연합조화대조조골수억제정황비교차이유통계학의의(χ2=4.91,P<0.05);연합조치료전후종류표지물급외주혈세포인자계수변화비교무통계학차이(P>0.05)。결론자체DC-CIK세포회수연합화료치료만기악성실체류DCR비단순화료자고,병차능구개선만기종류환자생존질량、KPS평분,감경화료후골수억제정황,단위장도반응무명현차이。종류표지물급세포인자무명현변화。
Objective To explore the curative effect in the near future that autologous DC-CIK cells transfusion com-bined with chemotherapy in the treatment of advanced malignant solid tumor. Methods Observed the curative effect that au-tologous DC-CIK cells transfusion combined with chemotherapy in the treatment of advanced malignant solid tumor , and the pe-ripheral blood cytokins, tumor markers, gastrointestinal reactions, bone marrow suppression,the quality of life,kamofsky grade. Results There was 0 case completely response (CR) in twenty advanced tumor patients that cured by chemotherapy, part re-sponse(PR) of 1 case,minimal remission (MR) of 2 cases,stable disease(SD) of 7 cases, progressive disease(PD) of 10 cases. The remission rate was 15%,disease control rate was 50%. There was 1 case of CR in united group, PR of 2 cases, MR of 4 cases,SD of 10 cases, PD of 3 cases. The remission rate was 35%,disease control rate was 85%. There were statistical signifi-cant differences between the two groups. For the cancerous pain,spirit condition,sleep,fatigue and weakness of qualitative index live marked improvement and bone marrow suppression. There were statistical significant differenece between the two groups. There were no statistical significant difference between the two groups on the tumor markers and peripheral bood cytokins. Conclusion The curative effect that autologous DC-CIK cells transfusion combined with chemotherapy in the treatment of ad-vanced malignant solid tumor is better than that cured by chemotherapy. It improves the life quality of advanced tumor patients and kamofsky grade,reduces bone marrow suppression,doesn't increase gastrointestinal reactions, tumor makers and blood cy-tokins don't change.